Navigation Links
Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process
Date:4/2/2008

WASHINGTON DC, April 2 /PRNewswire-FirstCall/ -- Bavarian Nordic, the Danish-based biopharmaceutical company, recently published its 2007 Annual Report. Below is an extract of the most significant matters in the report as well as events after the balance sheet date.

Bavarian Nordic's revenue for the year 2007 was DKK 332.1 million with a loss before tax of DKK 50.5 million, which was in line with the Company's latest guidance. For 2008, Bavarian Nordic expects revenue in the region of DKK 180 million, and a pre-tax loss in the region of DKK 225 million as the first deliveries of vaccines for the US government under the RFP-3 contract are not expected to take place before 2009.

2007 outline

The year 2007 was a busy and eventful year, but also a very successful year. With the award of the RFP-3 contract from the US authorities Bavarian Nordic fulfilled the most important milestone in the history of the Company. The contract was awarded after prolonged negotiations in which the Company succeeded, as the first in the world, in obtaining advance and milestone payments under Project BioShield. In addition to the base contract of USD 500 million for the delivery of 20 million doses of the company's third-generation smallpox vaccine, IMVAMUNE(R), the contract includes an option contract of USD 1.1 billion for the delivery of an additional 60 million doses.

After the RFP-3 contract was signed, Bavarian Nordic successfully fulfilled all the requirements relating to the development of physical safety, IT security, validation of production and test processes, etc. underlying the advance payment of USD 50 million and the two milestone payments of USD 25 million each. These payments helped make the current financial position the best ever in the Company's history.

In our pipeline, we have presented important data on IMVAMUNE(R). Three out of five Phase II studies have been completed and show very promising results. When the HIV Phase II-d
'/>"/>

SOURCE Bavarian Nordic A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Bavarian Nordic Receives $50 Million Advance Payment from HHS for Fulfilling Contract Milestones
2. Vista Partners Updates Coverage; Maintains $3.20 Target Price
3. ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
4. NanoLogix Inc. Presents at the National Hydrogen Association Conference & Provides Operations, Management and Director Update
5. SGX Pharmaceuticals Provides Update on SGX523 Clinical Trials
6. ImaRx Reschedules Release of Corporate Updates and Fourth Quarter and Full Year 2007 Financial Results
7. ImaRx to Report Corporate Updates and 4Q07 Financial Results
8. LUMEDX Updates Real-Time Patient and Resource Scheduler for Healthcare Systems
9. InfuSystem Holdings Provides Business Update and Comments on Fourth Quarter 2007 Financial Results
10. Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008
11. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... (PRWEB) April 21, 2015 Progyny, Inc., ... Authority, LLC, announced that it has secured additional capital ... TPG Biotech, SR One and Merck Serono Ventures. The ... provide patients the best fertility outcomes by aligning science, ... largest online marketplace for families seeking fertility solutions and ...
(Date:4/21/2015)... A leading manufacturer of stainless steel ... discuss its custom fabrication services today at INTERPHEX 2015. ... launched just prior to the INTERPHEX event. The expo ... and 23) at the Javits Center in New York ... largest and most innovative pharmaceutical and biotech firms will ...
(Date:4/21/2015)... YourEncore, an Indianapolis, Indiana-based company ... products and food sciences industries solve complex development, ... Clinical Research Excellence and Safety (ACRES), a Massachusetts-based ... research, have partnered to speed innovation in the ... brings to ACRES experts with proven experience, tools, ...
(Date:4/20/2015)... and MENLO PARK, Calif. ... Inc. (OTCQX: DMPI) (DelMar and the Company), ... proven cancer therapies in new orphan drug indications, ... 106th Annual Meeting of the American Association for ... potential for its lead product candidate VAL-083 ...
Breaking Biology Technology:Announcing Progyny: Combining Best-in-Class Clinical Solutions with Consumer Expertise 2HOLLOWAY AMERICA to Reveal Newly Designed Responsive Website at INTERPHEX 2015 Today 2HOLLOWAY AMERICA to Reveal Newly Designed Responsive Website at INTERPHEX 2015 Today 3YourEncore and ACRES Partner to Drive Innovation in Clinical Research 2YourEncore and ACRES Partner to Drive Innovation in Clinical Research 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 2DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 4DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 5
... 28, 2010 "More than meets the eye" may soon ... popular robotic toys. Researchers at Harvard and MIT have ... that rely on the ancient art of origami. Called ... thin sheet composed of interconnected triangular sections could transform itself ...
... CLEVELAND , June 28 Arteriocyte, Inc., ... a Venture of Year Award Finalist. Founded in 2004 ... therapies, Arteriocyte focuses on developing commercially available stem cell ... cells (marrow, peripheral cord blood, and cartilage) for delivery ...
... , DALLAS , June 28, 2010 ... - High Unmet Needs,Triggering Strong Growth in Crohn,s Disease and Irritable Bowel ... , , ... http://www.reportsandreports.com/market-reports/gastrointestinal-disorders-th ,erapeutics-to-2016-high-unmet-need/ , , , ...
Cached Biology Technology:Shape-shifting sheets automatically fold into multiple shapes 2Arteriocyte Named Top Biotech Start Up Venture by the Ohio Venture Association for 2010 2Arteriocyte Named Top Biotech Start Up Venture by the Ohio Venture Association for 2010 3Gastrointestinal Disorders Therapeutics to 2016 - High Unmet Needs Triggering Strong Growth in Crohn's Disease and Irritable Bowel Syndrome Markets Now Available at ReportsandReports 2Gastrointestinal Disorders Therapeutics to 2016 - High Unmet Needs Triggering Strong Growth in Crohn's Disease and Irritable Bowel Syndrome Markets Now Available at ReportsandReports 3Gastrointestinal Disorders Therapeutics to 2016 - High Unmet Needs Triggering Strong Growth in Crohn's Disease and Irritable Bowel Syndrome Markets Now Available at ReportsandReports 4Gastrointestinal Disorders Therapeutics to 2016 - High Unmet Needs Triggering Strong Growth in Crohn's Disease and Irritable Bowel Syndrome Markets Now Available at ReportsandReports 5Gastrointestinal Disorders Therapeutics to 2016 - High Unmet Needs Triggering Strong Growth in Crohn's Disease and Irritable Bowel Syndrome Markets Now Available at ReportsandReports 6Gastrointestinal Disorders Therapeutics to 2016 - High Unmet Needs Triggering Strong Growth in Crohn's Disease and Irritable Bowel Syndrome Markets Now Available at ReportsandReports 7Gastrointestinal Disorders Therapeutics to 2016 - High Unmet Needs Triggering Strong Growth in Crohn's Disease and Irritable Bowel Syndrome Markets Now Available at ReportsandReports 8Gastrointestinal Disorders Therapeutics to 2016 - High Unmet Needs Triggering Strong Growth in Crohn's Disease and Irritable Bowel Syndrome Markets Now Available at ReportsandReports 9Gastrointestinal Disorders Therapeutics to 2016 - High Unmet Needs Triggering Strong Growth in Crohn's Disease and Irritable Bowel Syndrome Markets Now Available at ReportsandReports 10Gastrointestinal Disorders Therapeutics to 2016 - High Unmet Needs Triggering Strong Growth in Crohn's Disease and Irritable Bowel Syndrome Markets Now Available at ReportsandReports 11Gastrointestinal Disorders Therapeutics to 2016 - High Unmet Needs Triggering Strong Growth in Crohn's Disease and Irritable Bowel Syndrome Markets Now Available at ReportsandReports 12Gastrointestinal Disorders Therapeutics to 2016 - High Unmet Needs Triggering Strong Growth in Crohn's Disease and Irritable Bowel Syndrome Markets Now Available at ReportsandReports 13Gastrointestinal Disorders Therapeutics to 2016 - High Unmet Needs Triggering Strong Growth in Crohn's Disease and Irritable Bowel Syndrome Markets Now Available at ReportsandReports 14Gastrointestinal Disorders Therapeutics to 2016 - High Unmet Needs Triggering Strong Growth in Crohn's Disease and Irritable Bowel Syndrome Markets Now Available at ReportsandReports 15Gastrointestinal Disorders Therapeutics to 2016 - High Unmet Needs Triggering Strong Growth in Crohn's Disease and Irritable Bowel Syndrome Markets Now Available at ReportsandReports 16Gastrointestinal Disorders Therapeutics to 2016 - High Unmet Needs Triggering Strong Growth in Crohn's Disease and Irritable Bowel Syndrome Markets Now Available at ReportsandReports 17Gastrointestinal Disorders Therapeutics to 2016 - High Unmet Needs Triggering Strong Growth in Crohn's Disease and Irritable Bowel Syndrome Markets Now Available at ReportsandReports 18Gastrointestinal Disorders Therapeutics to 2016 - High Unmet Needs Triggering Strong Growth in Crohn's Disease and Irritable Bowel Syndrome Markets Now Available at ReportsandReports 19Gastrointestinal Disorders Therapeutics to 2016 - High Unmet Needs Triggering Strong Growth in Crohn's Disease and Irritable Bowel Syndrome Markets Now Available at ReportsandReports 20Gastrointestinal Disorders Therapeutics to 2016 - High Unmet Needs Triggering Strong Growth in Crohn's Disease and Irritable Bowel Syndrome Markets Now Available at ReportsandReports 21Gastrointestinal Disorders Therapeutics to 2016 - High Unmet Needs Triggering Strong Growth in Crohn's Disease and Irritable Bowel Syndrome Markets Now Available at ReportsandReports 22Gastrointestinal Disorders Therapeutics to 2016 - High Unmet Needs Triggering Strong Growth in Crohn's Disease and Irritable Bowel Syndrome Markets Now Available at ReportsandReports 23Gastrointestinal Disorders Therapeutics to 2016 - High Unmet Needs Triggering Strong Growth in Crohn's Disease and Irritable Bowel Syndrome Markets Now Available at ReportsandReports 24Gastrointestinal Disorders Therapeutics to 2016 - High Unmet Needs Triggering Strong Growth in Crohn's Disease and Irritable Bowel Syndrome Markets Now Available at ReportsandReports 25Gastrointestinal Disorders Therapeutics to 2016 - High Unmet Needs Triggering Strong Growth in Crohn's Disease and Irritable Bowel Syndrome Markets Now Available at ReportsandReports 26
(Date:4/2/2015)... 2015 According to preliminary estimates ... somewhat higher than 125 MSEK. This exceeds the guidance ... that revenues for Q1 2015 would be in line ... Q4 2014. The operating result for the first quarter ... interim report will as previously communicated be published on ...
(Date:3/31/2015)...   Guidepoint , a leading global research services ... Management TRACKER, part of the Guidepoint TRACKER ... medical device and therapeutics markets. The Post-Surgical Pain Management ... market share, and adoption rates across three major modalities ... The Post-Surgical Pain Management TRACKER will provide ...
(Date:3/24/2015)... --  NexID Biometrics LLC, whose spoof-mitigation technology boosts ... the beginning of shipments of version 2.0 of its ... based in Potsdam, N.Y. , is ... began here today at the Walter E. Washington Convention ... SDK boosts the accuracy rate range to 96.5 to ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... (Nasdaq: MEAS ), a designer and manufacturer of ... adopted German,Business Tax Reform 2008 on current year financial ... became effective on August,17, 2007, reduces the corporate income ... combined German tax rate from approximately 39% to 31%.,Although ...
... N.J. The examination of clinical, technical, managerial and ... asthmatic and COPD (Chronic Obstructive Pulmonary Disease) patient will ... healthcare roundtable, to be held Wednesday, October 31, 2007, ... Center (located on 6th and River Streets in Hoboken, ...
... role of fibroblast growth factor (FGF) in the embryonic ... in a paper posted to the Web site of ... November print issue of the journal. The ... and the lab team has made significant contributions to ...
Cached Biology News:Measurement Specialties, Inc. Announces Impact of 'German Business Tax Reform 2008' Resulting in Lower Combined German Tax Rate - Impacts 2Q08 Reported Financial Results 2Measurement Specialties, Inc. Announces Impact of 'German Business Tax Reform 2008' Resulting in Lower Combined German Tax Rate - Impacts 2Q08 Reported Financial Results 3Stevens Health, Technology, and Society roundtable: Oct. 31 2Pourquie Lab demonstrates role of growth factor in vertebrae formation 2
... Bio-Plex maintenance, calibration, and validation ... custom 96-well plate used for ... calibration procedures using the Bio-Plex ... plate is for use with ...
Mynox is intended for research use only. Mynox is used for the elimination of Mycoplasma and Acholeplasma in cell and virus cultures, and other biologicals....
... real-time PCR detection system holds 48 x 0.2 ... of 48 LEDs independently excites fluorescence (470-500 nm) ... photodiodes detects emitted light (523-543 nm and 540-700 ... Mini cycler, whose Peltier heat pumps provide superb ...
... The MiniOpticon 2-color real-time PCR detection system holds 48 ... array of 48 LEDs independently excites fluorescence (470-500 nm) ... detects emitted light (523-543 nm and 540-700 nm). This ... MJ Mini thermal cycler. System dimensions are 18 x ...
Biology Products: